371PPalbociclib plus fulvestrant as second- or later-line...

Annals of Oncology 2019 / 10 Vol. 30; Iss. Supplement

371PPalbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

Lüftner, D, Welslau, M K, Liersch, R, Deryal, M, Brucker, C, Rauh, J, Welt, A, Zaiss, M, Sahlmann, J, Houet, L, Vannier, C, Potthoff, K, Marschner, N W
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz242.066
Date:
October, 2019
File:
PDF, 80 KB
2019
Conversion to is in progress
Conversion to is failed